Belite Bio (BLTE) Leases (2022 - 2025)

Belite Bio's quarterly Leases came in at $433000.0 in Q4 2025, down 16.89% year-on-year from $521000.0 in Q4 2024, and down 16.89% quarter-over-quarter from $521000.0 in Q4 2024.

Belite Bio has reported Leases for 4 years, with the latest figure at $433000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Leases fell 16.89% year-over-year to $433000.0; the trailing twelve-month figure through Dec 2025 stood at $433000.0 (down 16.89% YoY), and the FY2025 full-year result was $433000.0, down 16.89% from the prior year.
  • Leases for Q4 2025 stood at $433000.0, down from $521000.0 in the prior quarter.
  • The five-year high for Leases was $811000.0 in Q4 2023, with the low at $433000.0 in Q4 2025.
  • Average Leases over 4 years is $642750.0, with a median of $663500.0 recorded in 2022.
  • Year-over-year, Leases increased 0.62% in 2023 and plunged 35.76% in 2024.
  • Tracing BLTE's Leases over 4 years: stood at $806000.0 in 2022, then increased by 0.62% to $811000.0 in 2023, then sank by 35.76% to $521000.0 in 2024, then retreated by 16.89% to $433000.0 in 2025.
  • The last three Leases figures came in at $433000.0 (Q4 2025), $521000.0 (Q4 2024), and $811000.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Leases (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 83,048.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 61,822.50
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 285.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.69 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 189.30 Mn
10 Belite Bio 4.92 Bn 4.45 Bn - 433,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 433,000.00
Sep 30, 2025 509,000.00
Dec 31, 2024 521,000.00
Dec 31, 2023 811,000.00
Dec 31, 2022 806,000.00